CMV Immunity Monitoring in Lung Transplant Recipients

Recruiting now · Phase 2

Conditions studied: Lung Transplant; Complications

In brief

The purpose of this study is to determine the safety and feasibility of using a laboratory test to guide duration of antiviral prophylaxis with valganciclovir (medication used to prevent viral infections) after lung transplant. The laboratory test, inSIGHT™ CMV T Cell Immunity Panel, measures patients' immune response to a common viral infection known as cytomegalovirus (CMV). The goal of this study will be to safely decrease how long patients need to take valganciclovir based on the results of the CMV T Cell Immunity Panel.

Key facts

Study ID

NCT05708755

Run by

NYU Langone Health

People needed

50

Starts

2024-09-13

Expected to finish

2028-05-01

Last updated by the study team

2026-05-29

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Received a lung transplant, or multi-organ transplant involving a lung at NYU Langone Health
• Pre-existing serological immunity to CMV (R+)
• Able and willing to provide informed consent

You may not qualify if…

• Anti-thymocyte globulin induction immunosuppression
• Perioperative desensitization
• Pregnant or breastfeeding women

Where it is running

• NYU Langone Health — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.